Mumbai: Pharma Major Lupin announced that it has received final approval for its Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg from the United States Food and Drug Administration (FDA) to market a generic version of US WorldMeds, LLC’s Corgard® Tablets, 20 mg, 40 mg, and 80 mg.

Lupin’s Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg are the AB rated generic equivalent of US WorldMeds, LLC’s Corgard® Tablets, 20 mg, 40 mg, and 80 mg. They are indicated for management of patients with angina pectoris and for the treatment of hypertension.

Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg Tablets had annual sales of approximately USD 109.8 million in the US (IMS MAT June 2017).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 7^th and 6^th largest generics pharmaceutical company by market capitalization (June 30^th, 2017, Bloomberg) and revenues (March 31^st, 2017, Bloomberg) respectively. The Company is the 4^th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2^nd largest Indian pharmaceutical company by global revenues (March 31^st, 2017, Bloomberg); 6^th largest generic pharmaceutical player in Japan and 6^th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).

For the financial year ended 31^st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –Pooja ThakranVP – Corporate CommunicationsEmail: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225 Arvind BothraHead – Investor Relations and M&AEmail: arvindbothra@lupin.com  Ph: +91-22-66402137

*Safe Harbor Statement

Corgard ® is a registered trademark of E.R. Squibb & Sons, LLC.